2020 Medicinal Chemistry Reviews

Volume 55
Joanne J. Bronson, Editor-In-Chief

Medicinal Chemistry Reviews is an outstanding 830 page volume providing timely and critical reviews of important topics in medicinal chemistry. It is provided free of charge to MEDI members in electronic format. Members can also order a print copy, for the cost of printing, shipping and handling (price to be determined).

Members: To access your copy:

--Click 'Member Login' in the upper right corner of this page
--On the Member Login page, click the 'Resources' tab.

Nonmembers wishing to purchase a copy may click here and purchase at the non-member price.

Libraries and institutions interested in purchasing a copy should contact the Division Secretary, secretary@acsmedchem.org.

Table of Contents:

Chapter 1	Drug Discovery: Ingenuity and Serendipity...Or is It the Other Way Around? Richard B. Silverman
Chapter 2	The Making of a Drug-Hunting Addict Scott A. Biller
Chapter 3	Recent Progress in Neuroinflammatory Drug Targets David P. Rotella
Chapter 4	Recent Progress in Kappa and Mu Opioid Receptor Targeted Ligands Michael W. Miller, Brian Reed
Chapter 5	Engineered Heart Tissue: An Emerging Paradigm for Early Drug Screening Matthew J. Robeson, Kristin M. French
Chapter 6	Modulation of Soluble Guanylate Cyclase for the Treatment of Heart Failure and Related Cardiovascular Diseases Christopher R. Jamison, Andrew K. Dilger
Chapter 7	Recent Advances in the Discovery of NLRP3 Inflammasome Inhibitors David Harrison
Chapter 8	Advances in the Discovery and Development of Non-Covalent and Covalent BTK Inhibitors Targeting Autoimmune Diseases Scott H. Watterson and Joseph A. Tino
Chapter 9	TLR7, TLR8, and TLR9 Antagonists: Potential Therapies for Autoimmune Diseases Lynn D. Hawkins
Chapter 10	Clinical and pre-clinical approaches to the inhibition of KRASG12C Brian A. Lanman, Victor J. Cee, Matthew A. Marx
Chapter 11	Allosteric Inhibition of SHP2 Phosphatase Matthew J. LaMarche
Chapter 12	The Development of Tropomyosin Receptor Kinase (Trk) Inhibitors as Targeted Cancer Therapeutics Abhijit Bhat, Stephane Ciblat, Hong Wang, Kollol Pal
Chapter 13	Recent Progress in the Discovery and Clinical Application of Small-Molecule Inhibitors EZH2 and EED Julian R. Levell
Chapter 14	Quorum Sensing in Polymicrobial Infections: Analysis of Existing Small Molecule Modulators Nadezhda A. German
Chapter 15	Drug Target Residence Time and the Pharmacodynamics of Antibacterial Agents Sneha Basak, Peter J. Tonge
Chapter 16	The Drug Substances of Long-Acting Injectables: Examples from Hormone, CNS, and Antiviral Therapies Ana Z. Gonzalez, Scott V. Jermain, Ezra B. Roberts, Gregg M. Schwarzwalder
Chapter 17	Targeting Nuclear Export for Treatment of Cancers and Other Diseases Hanmo Zhang, Dejan Maglic
Chapter 18	Proteasome Activation to Restore Protein Trafficking: A Different Perspective on the Ubiquitin-Proteasome System Bhaumik A. Pandya, Stephen J. Wood
Chapter 19	RNA-Modifying Enzymes and Their Inhibitors Wesley Peter Blackaby, Byron Andrews, Beth Thomas, David Hardick, Eric A. Miska
Chapter 20	Recent Developments in IKB Kinases IKK-ε and Tank-Binding Kinase 1 (TBK1) Modulators Amit A. Joharapurkar, Vrajesh B. Pandya, Mukul R. Jain, Ranjit C. Desai
Chapter 21	Design Strategies for Second-Generation Irreversible Covalent Inhibitors of Bruton’s Tyrosine Kinase Hui Qiu, Momar Toure, Rebecca L. Casaubon, Maria C. DiPoto, Roland Grenningloh, Richard D. Caldwell
Chapter 22	Therapeutic Degradation of Protein Kinases Through PROTACs: Current Status and Future Potential Li Zhang, Campbell McInnes
Chapter 23	DNA-Encoded Libraries in the Pharmaceutical Industry Alexander L. Satz, Christopher S. Kollmann, Brian M. Paegel
Chapter 24	Case History: Tpoxx® (Tecovirimat)—A Novel Orthopoxvirus Egress Inhibitor for the Treatment of Smallpox Robert Jordan, Doug Grosenbach, James Burgeson, Dennis Hruby
Chapter 25	Case History: Eucrisa® (Crisaborole Ointment, 2%), A Boron-Based PDE4 Inhibitor for the Topical Treatment of Atopic Dermatitis Matthew A. Perry
Chapter 26	New Chemical Entities Entering Phase III Trials in 2019 Matthew L. Condakes, Anna E. Hurtley, David W. Lin, Gregory T. Notte, Vickie Tsui, Nathan E. Wright, Alec H. Christian
Chapter 27	To Market, to Market—2019: Small Molecules Erika Araujo, Catherine A. Bolger, Marie-Gabrielle Braun, Georgette Castanedo, Mingshuo Zeng, Adam K. Charnley, Antonella Converso, Izzat T. Raheem, Anthony J. Roecker, Akshay A. Shah, T. G. Murali Dhar, Denise C. Grünenfelder, J. Robert Merritt, Kevin M. Peese
Chapter 28	To Market, to Market—2019: Macromolecular Therapeutics Nicholas J. Agard, Peter S. Dragovich, Allison M. Beal, Catherine A. Bolger, Suzana A. Kahn, Brant Hubbard, Daša Lipovšek

2020 Medicinal Chemistry Reviews

ACS Division of Medicinal Chemistry